Boston Scientific has European CE clearance to begin marketing a private-label XIENCE V everolimus-eluting coronary stent made by Abbott Vascular. The stent, named PROMUS, makes BSC the only company offering two distinct DES platforms in the CE geographies.
The company can market PROMUS in the 25 countries of the European Union; the CE mark also supports market registrations in other regulated countries in Asia, Latin America and Eastern Europe.
The addition of PROMUS complements Boston Scientific's TAXUS paclitaxel-eluting stent systems. The company says it expects to launch the PROMUS stent in Europe in 2007.